18. Masuoka HC, Chalasani N.Nonalcoholic fatty liver disease: an emerging threat to obese and dia- betic individuals.Ann N Y Acad Sci. 2013 Jan 30


19. Monsour HP Jr, Frenette CT, Wyne K Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012 Jul-Sep;8(3):21-5.


20. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M.Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012 Nov;91(6):319-27.


21. Arienti V, Aluigi L, Pretolani S, Accogli E, Poli- meni L, Domanico A, Violi F Ultrasonography (US) and non-invasive diagnostic methods for non-alco- holic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS).Intern Emerg Med. 2012 Oct;7 Suppl 3:S283-90.


22. Hurjui DM, Niţă O, Graur LI, Mihalache L, Popescu DS, Graur M.The central role of the non alcoholic fatty liver disease in metabolic syn- drome.Rev Med Chir Soc Med Nat Iasi. 2012 Apr- Jun;116(2):425-31.


23. Magosso E, Ansari MA, Gopalan Y, et al. (2010). Tocotrienols and Nonalcoholic Fatty Liver: a Clin- ical Experience. 61st Liver Meeting, American As- sociation for the Study of Liver Diseases (AASLD). 28 October-2 November 2010, Hynes Convention Center, Boston, MA (USA). In Hepatology 2010;52(4 Supp):642.


24. Patel V, Rink C, Gordillo GM, Khanna S, Gnyawali U, Roy S, Shneker B, Ganesh K, Phillips G, More JL, Sarkar A, Kirkpatrick R, Elkhammas EA, Klatte E, Miller M, Firstenberg MS, Chiocca EA, Nesaretnam K, Sen CK. Oral tocotrienols are trans- ported to human tissues and delay the progression of the model for end-stage liver disease score in pa- tients. J Nutr. 2012 Mar;142(3):513-9.


25. Gyamfi MA, Damjanov I, French S, Wan YJ.. The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem Pharmacol 2008;75(4):981-995.


26. Kuhad A, Chopra K. Attenuation of diabetic ne- phropathy by tocotrienol: involvement of NFkB sig- naling pathway.Life Sci. 2009 Feb 27;84(9-0):296-301.


27. Rasool AH, Rahman AR, Yuen KH, Wong AR.Ar- terial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vita- min E.Arch Pharm Res. 2008 Sep;31(9):1212-7.


28. Rasool AH, Yuen KH, Yusoff K, Wong AR, Rah- man AR.Dose dependent elevation of plasma tocot- rienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E.J Nutr Sci Vitaminol (Tokyo). 2006 Dec;52(6):473-8.


29. Correll CC, Ng L, Edwards PA. Identification of farnesol as the non-sterol derivative of mevalo- nic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.


J Biol Chem 1994, 269:17390-17393.


30. Qureshi AA, Sami SA, Salser WA, Khan FA. Syn- ergistic effect of tocotrienol-rich fraction (TRF(25)) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans. J Nutr Biochem. 2001 June 12(6):318-329


31. Yuen Kah Hay Yuen, Jia Woei Wong, Ai Beoy Lim, Bee Hong Ng, Wai Peng Choy. Effect of Mixed-To- cotrienols in Hypercholesterolemic Subjects. Func- tional Foods in Health and Disease: 3:106-117


32. Khanna S, Roy S, Park HA, Sen CK. Regulation of c-Src activity in glutamate-induced neurodegen- eration. J Biol Chem. 2007 Aug 10;282(32):23482-90. PMID: 17569670


33. Das S, Mukherjee S, Lekli I, Gurusamy N, Bard- han J, Raychoudhury U, Chakravarty R, Banerji S, Knowlton AA, Das DK. Tocotrienols confer resis- tance to ischemia in hypercholesterolemic hearts: insight with genomics. Mol Cell Biochem. 2012 Jan;360(1-2):35-45.


34. Kaileh M, Sen R. Role of NF-kappaB in the an- ti-inflammatory effects of tocotrienols.J Am Coll Nutr. 2010 Jun;29(3 Suppl):334S-339S.


35. Wolf G. How an increased intake of alpha-to- copherol can suppress the bioavailability of gam- ma-tocopherol. Nutr Rev. 2006 Jun;64(6):295-9. PMID: 16808116


From a Single Cell to the


Human Brain: A Lifelong Journey An Interview with Chandan K Sen, PhD


A Note from Stephen Levine: When Focus decided to delve deeper into the unique healing potential of tocotrienols, we had the honor of interviewing a towering figure in the field: Dr. Chandan Sen, tenured Professor of Surgery and the Executive Director of the Ohio State University Comprehensive Wound Center. Dedicated to tocotrienol research for decades, Sen has unswervingly pursued his passion since his staff scientist days at the University of California at Berkeley, working with famed mentor Lester Packer PhD. Sen’s research offers impressive evidence that these tiny, powerful molecules may help to minimize deadly strokes and aid in


Focus: You’ve done remarkable work on tocotrienols, particular- ly alpha tocotrienol, and the pos- sible prevention of stroke, and


recovery for those already affected.


The pursuit has been, as Sen reflects in this interview, “a long journey of learning. Part of the challenge was learning how to progress from a model of research on the molecule to a single cell to small animals to large animals and then to humans, all the while strictly following every regulation and all the ethics required.” Ethics, might I add, that went beyond the call of duty—where Sen and his colleagues found a new way to do research on canine brains, and in human brains and organs (in the living organism) that was minimally invasive and quite remarkable. –Stephen Levine, PhD


repair of damage in stroke. What got you interested in tocotrienols in the first place?


Sen: I was at Berkeley, and my


supervisor was Lester Packer, arguably the most cited and ac- tive person in Vitamin E research at that time. I asked Lester, ‘Why


Focus April 2013 9


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28